

BAXTER INTERNATIONAL INC.
Key Product Line Sales by U.S. and International
Three-Month Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

| | Q2 2011 | | | Q2 2010 | | | % Growth | | |
|--|----------------|----------------|----------------|----------------|----------------|----------------|-----------|---------------|--------------|
| | U.S. | International | Total | U.S. | International | Total | U.S. | International | Total |
| BioScience | | | | | | | | | |
| Recombinants | \$239 | \$331 | \$570 | \$233 | \$292 | \$525 | 3% | 13% | 9% |
| Plasma Proteins | 103 | 260 | 363 | 110 | 204 | 314 | (6%) | 27% | 16% |
| Antibody Therapy | 261 | 120 | 381 | 211 | 99 | 310 | 24% | 21% | 23% |
| Regenerative Medicine | 78 | 69 | 147 | 76 | 57 | 133 | 3% | 21% | 11% |
| Other ¹ | 6 | 86 | 92 | 6 | 70 | 76 | 0% | 23% | 21% |
| Total BioScience | \$687 | \$866 | \$1,553 | \$636 | \$722 | \$1,358 | 8% | 20% | 14% |
| Medical Products² | | | | | | | | | |
| Renal | \$97 | \$536 | \$633 | \$98 | \$487 | \$585 | (1%) | 10% | 8% |
| Global Injectables | 255 | 251 | 506 | 263 | 209 | 472 | (3%) | 20% | 7% |
| IV Therapies | 144 | 308 | 452 | 134 | 284 | 418 | 7% | 8% | 8% |
| Infusion Systems | 137 | 96 | 233 | 132 | 84 | 216 | 4% | 14% | 8% |
| Anesthesia | 88 | 55 | 143 | 84 | 46 | 130 | 5% | 20% | 10% |
| Other 1 | | 5 | 6 | (1) | 4 | 3 | N/M | 25% | 100% |
| Total Medical Products | \$722 | \$1,251 | \$1,973 | \$710 | \$1,114 | \$1,824 | 2% | 12% | 8% |
| Transfusion Therapies³ | \$9 | \$1 | \$10 | \$9 | \$3 | \$12 | 0% | (67%) | (17%) |
| Total Baxter | \$1,418 | \$2,118 | \$3,536 | \$1,355 | \$1,839 | \$3,194 | 5% | 15% | 11% |

¹ Principally includes vaccines and sales of plasma to third parties.

² Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

³ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.